OBJECTIVE: This study evaluated serum levels of the neuropeptides calcitonin gene-related peptide (CGRP) and substance P (SP) in coronary artery disease (CAD) patients with and without a history of diabetes mellitus (DM). METHODS: Patients undergoing coronary angiography for suspected myocardial ischaemia were divided into four groups depending on their clinical status: control group (no CAD or DM; n = 44), DM group (DM without CAD; n = 46), CAD group (stable CAD without DM; n = 44) and DM + CAD group (stable CAD with DM; n = 50). Serum levels of CGRP and SP were determined using radioimmunoassays. RESULTS: CGRP and SP levels in the DM and CAD groups were significantly lower than in the control group. The lowest levels of CGRP and SP were observed in the DM + CAD group. There were no significant differences in CGRP and SP levels between the DM group and the CAD group. CONCLUSION: CGRP and SP may have a role in the pathogenesis of CAD in patients with diabetes.
Introduction
Diabetes mellitus (DM) is one of the most important risk factors for cardiovascular diseases and many patients with diabetes develop diffused stenosis of the coronary arteries leading to myocardial infarction and cardiomyopathy. 1 Current guidelines consider diabetes per se to be a coronary artery disease (CAD) risk equivalent. 2 Hyperglycaemia is present in the majority of patients with CAD at a far higher prevalence than in the general population (estimated to be 7.0% in the USA), 3 -5 but the underlying mechanism for this association is not clear.
In patients with diabetes, the development of sensory polyneuropathy is frequently associated with symptoms that may result from functional and structural alterations to nociceptive neurons. 6 Transient receptor potential vanilloid 1 (TRPV1) and its main neuropeptides, calcitonin gene-related peptide (CGRP) and LH Wang, SX Zhou, RC Li et al. CGRP and substance P in diabetes and coronary artery disease substance P (SP), in cardiac sensory nerves were found to be impaired in diabetes. 7 Several lines of evidence suggest that TRPV1, CGRP and SP may be involved in the regulation of cardiovascular haemodynamics and may have a role in myocardial ischaemia. 8 -10 In addition, decreased expression of cardiac TRPV1, CGRP and SP in diabetes is associated with poor recovery of cardiac function after myocardial ischaemia. 11 It is, therefore, possible that impaired CGRP and SP expression may be related to the high prevalence of CAD in patients with diabetes.
The aim of the present study was to examine serum levels of CGRP and SP in CAD patients with and without a known history of diabetes.
Patients and methods

STUDY POPULATION AND DESIGN
Consecutive Chinese patients with or without diabetes and aged between 40 and 70 years who underwent coronary angiography for suspected myocardial ischaemia at The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China were recruited to the study between May 2009 and March 2010. For the purposes of this study diabetes was defined as type 2 diabetes mellitus with onset at ≥ 30years-old and no history of ketoacidosis. The presence of CAD was defined as a stenotic lesion of at least 50% in one or more major coronary arteries or the main coronary artery on angiography. Exclusion criteria included: (i) unstable CAD (changes in CAD symptoms in the previous 60 days); (ii) acute coronary syndrome;
(iii) coronary angiography within the previous 3 years; ( 
LABORATORY ASSAYS
Venous blood samples were taken in the early morning (07.00 h) after overnight fasting before coronary artery angiography was performed. Blood was collected into tubes containing heparin (20 U/ml blood) for measurement of fasting plasma glucose and tubes without heparin for measurement of CGRP and SP. All serum samples were frozen soon after the blood was obtained and stored at -70°C until use. Fasting plasma glucose (FPG) was quantified using the glucose oxidase method. 12 Commercially available CGRP and SP radioimmunoassay kits (Huaying Biological Engineering, Beijing, China) were used to determine serum CGRP and SP levels, according to the manufacturer's instructions and as described previously. 7,8
STATISTICAL ANALYSES
Data are expressed as mean ± SD. Repeated measures one-way analysis of variance was used to determine the significance of trends within groups. Numerical data were compared using the χ 2 -test. A P-value < 0.05
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was considered to be statistically significant. Statistical analyses were performed using SPSS ® statistical package, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® .
Results
A total of 184 patients who underwent coronary angiography for suspected myocardial ischaemia were included in the study. Of these, 44 had neither CAD nor diabetes (control group), 46 had diabetes but not CAD (DM group), 44 had stable CAD but not diabetes (CAD group) and 50 had both diabetes and stable CAD (DM + CAD group). The similar numbers of patients in each group was an experimental finding.
The demographic and clinical characteristics of the patients in the four groups are given in Table 1 . There were no significant between-group differences in age or gender. The level of FPG was significantly higher in patients with diabetes (DM group and DM + CAD group) compared with patients without diabetes (control group and CAD group; P < 0.05 for all comparisons). There were no significant differences in FPG level or diabetes duration between diabetes patients with and without CAD.
Levels of serum CGRP in the DM group and CAD group were significantly lower than in the control group (P < 0.05 for both comparisons; Fig. 1 ). The lowest serum CGRP levels were observed in the DM + CAD group (P < 0.05 compared with all other groups; Fig. 1 ). There was no significant difference in serum CGRP levels between the DM group and the CAD group.
Serum SP levels were significantly lower in both the DM group and the CAD group than in the control group (P < 0.05 for both comparisons; Fig. 2 ). There was no significant difference in SP levels between the DM group and the CAD group. The SP levels in the DM + CAD group were significantly lower than in all other groups (P < 0.05 for all comparisons; Fig. 2 ).
Discussion
It is known that TRPV1 activation leads to release of neuropeptides such as SP, CGRP and other neurokinins from sensory nerve terminals. 13 -16 Among these sensory neuropeptides, CGRP has been shown to exert marked cardiostimulatory and coronary vasodilatory effects in pig and guinea-pig heart, 13,17 whereas SP appears primarily to cause coronary vasodilation. 13, 18 It has been shown that the heart is widely innervated by TRPV1-positive sensory nerves. 19 have been found at high densities in the right atrium, at the sinoatrial and atrioventricular nodes, in the pericardium and in the adventitia of the coronary arteries, mostly located in subepicardial and subendocardial tissues. 20, 21 The neuropeptides, CGRP and SP, exert a protective function in the cardiovascular system. 13,17,18,22 TRPV1 in cardiac sensory nerves has been shown to play an important role in protecting against myocardial ischaemia/reperfusion injury by increasing CGRP and SP release. 8 In the present study, mean serum CGRP and SP levels were significantly lower in patients with stable CAD than in controls. These results are consistent with previous reports comparing CGRP levels in patients with and without CAD 23 and indicate that SP and CGRP may play a role in the pathogenesis of CAD, with decreased release of CGRP and SP leading to impairment of their cardioprotective effects. Neurotransmitter levels have been shown to increase during stress, however, with a previous study in patients with acute myocardial infarction revealing an almost two-fold increase in plasma CGRP within 24 h of hospital admission. 24 The degeneration of sensory nerve fibres in diabetic neuropathy, a common complication of diabetes, has been demonstrated in both diabetic animals and patients. 25 -27 A previous study found that the release of both SP and CGRP in diabetic mouse hearts was markedly reduced compared with that in nondiabetic hearts. 7 In the present study, serum levels of CGRP and SP were decreased in patients with diabetes compared with controls; this impairment may be the result of diabetic cardiac autonomic neuropathy. 28 People with type 2 diabetes have twice the annual mortality rate of nondiabetic individuals, primarily due to cardiovascular disease. 29 A meta-analysis revealed that the rate of fatal CAD is higher in diabetic individuals than in nondiabetic individuals. 30 In addition, the incidence and severity of CAD events are higher in patients with diabetes. 29 In a large oral glucose tolerance test cohort study, 52.9% of CAD patients were diagnosed with diabetes and glucose regulation was impaired in a further 24.0% of CAD patients. 4 Hyperglycaemia is, therefore, a continuous risk factor for CAD, but the high incidence of CAD in patients with diabetes is currently unexplained. CGRP and SP primarily exert a cardioprotective function, 13, 17, 18, 22 and both DM patients and CAD patients had decreased serum CGRP and SP levels in the present study. Decreased serum CGRP and SP levels have been linked to poor recovery of cardiac function after myocardial ischaemia, 11 suggesting that the impaired release of neuropeptides may play a role in CAD pathogenesis in patients with diabetes.
A key finding in the present study was that the lowest serum CGRP and SP levels were observed in patients with both diabetes and CAD. This suggests there is a greater decrease in cardiac neuropeptide release or loss of neuropeptide-releasing nerve fibres in diabetic patients with CAD than in patients with diabetes or CAD alone. The effects of CGRP and SP on vasodilatation, vascular permeability, endothelial-associated inflamma tion and myocardial ischaemia suggest that they may have a role in CAD pathogenesis. 13, 17, 18, 22 The findings of the present study suggest that changes in neuropeptide levels may contribute to the high incidence of CAD in diabetic patients. It is possible that diabetes-associated neurodegeneration leads to significant changes in the global afferent innervation of the heart, resulting in decreased CGRP and SP release.
In conclusion, the high prevalence of CAD in patients with diabetes may be related to decreased serum levels of CGRP and SP. The development of drugs that can alter these neuropeptides might open up possibilities for the prevention and treatment of CAD in diabetic patients.
